Table 4.
Correlations of 13 miRNA involved in bone metastasis with OS since diagnosis and PFS and OS on 1st line VEGFR-TKI therapy (univariate Cox regression model).
| miRNA | OS Since Diagnosis | PFS on VEGFR-TKIs | OS on VEGFR-TKIs | |||
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Longer time to bone metastasis | ||||||
| miR-204-5p | 0.73 (0.65–0.82) | <0.001 | 0.84 (0.74–0.94) | 0.003 | 0.81 (0.72–0.92) | 0.001 |
| miR-30b-3p | 0.93 (0.78–1.10) | 0.386 | 1.07 (0.88–1.31) | 0.496 | 0.99 (0.81–1.21) | 0.921 |
| miR-542-5p | 0.85 (0.69–1.05) | 0.133 | 0.96 (0.77–1.20) | 0.728 | 0.89 (0.71–1.11) | 0.296 |
| miR-139-3p | 0.86 (0.73–1.00) | 0.057 | 0.91 (0.76–1.09) | 0.321 | 0.87 (0.73–1.03) | 0.105 |
| Shorter time to bone metastasis | ||||||
| miR-21-5p | 1.69 (1.31–2.18) | <0.001 | 1.14 (0.88–1.47) | 0.327 | 1.29 (1.01–1.65) | 0.043 |
| miR-21-3p | 1.50 (1.31–2.18) | <0.001 | 1.24 (1.04–1.48) | 0.016 | 1.35 (1.13–1.61) | 0.001 |
| miR-28-3p | 1.38 (0.98–1.93) | 0.064 | 1.01 (0.70–1.47) | 0.959 | 1.04 (0.72–1.50) | 0.823 |
| miR-34c-5p | 1.31 (1.16–1.48) | <0.001 | 1.19 (1.05–1.35) | 0.007 | 1.27 (1.11–1.44) | <0.001 |
| miR-23a-3p | 1.05 (0.83–1.33) | 0.697 | 0.98 (0.75–1.30) | 0.903 | 1.01 (0.76–1.34) | 0.953 |
| miR-20a-5p | 1.12 (0.91–1.39) | 0.279 | 0.95 (0.77–1.19) | 0.680 | 0.94 (0.75–1.18) | 0.598 |
| miR-335-3p | 1.22 (1.06–1.41) | 0.005 | 1.10 (0.95–1.26) | 0.193 | 1.11 (0.96–1.28) | 0.155 |
| miR-182-5p | 1.25 (1.09–1.43) | 0.002 | 1.11 (0.96–1.29) | 0.145 | 1.16 (1.01–1.34) | 0.040 |
| miR-27a-3p | 1.13 (0.87–1.47) | 0.351 | 0.87 (0.65–1.17) | 0.365 | 1.03 (0.77–1.39) | 0.831 |
Abbreviations: miRNA = microRNA; BM = bone metastasis; PFS = progression free survival; OS = overall survival; VEGFR-TKI = vascular endothelial growth factor receptor tyrosine kinase inhibitor; HR = hazard ratio; CI = confidence interval; miR = microRNA. Significant correlations (p-value < 0.05) are highlighted in bold.